Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon in relapsing-remitting multiple sclerosis.

G P Rice1, B Incorvaia, L Munari

  • 1Clinical Neurological Sciences, University of Western Ontario, 339 Windermere Road, London, Ontario, Canada, N6A 5A5. grice@julian.uwo.ca

The Cochrane Database of Systematic Reviews
|November 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transgenerational plasticity responses of larvae of Sydney rock oysters (Saccostrea glomerata) to ocean warming.

Marine pollution bulletin·2025
Same author

Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial.

ESMO open·2025
Same author

Corrigendum to [Effects of a new compound containing Palmitoylethanolamide and Baicalein in myocardial ischaemia/reperfusion injury in vivo] [PHYMED: 2019 Feb 15;54:27-42 Epub 2018 Sep 19].

Phytomedicine : international journal of phytotherapy and phytopharmacology·2023
Same author

Impact of sarcopenia in SARS-CoV-2 patients during two different epidemic waves.

Clinical nutrition ESPEN·2022
Same author

Wireless phone use in childhood and adolescence and neuroepithelial brain tumours: Results from the international MOBI-Kids study.

Environment international·2022
Same author

Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Recombinant interferons modestly reduced relapsing remitting multiple sclerosis (RRMS) exacerbations and disease progression in a Cochrane review. However, trial limitations, including dropouts and side effects, impacted definitive conclusions on interferon efficacy.

Area of Science:

  • Neuroimmunology
  • Clinical Therapeutics

Background:

  • Recombinant interferons are utilized to manage disease activity in relapsing remitting multiple sclerosis (RRMS).
  • Previous studies indicated potential suppression of clinical and MRI measures of disease activity.

Purpose of the Study:

  • To conduct a Cochrane review of randomized, placebo-controlled trials evaluating recombinant interferons in RRMS patients.
  • To synthesize evidence on the efficacy and safety of interferon therapy for RRMS.

Main Methods:

  • Systematic review of randomized, double-blind, placebo-controlled trials of recombinant interferon in RRMS.
  • Included seven trials with variable methodological quality, including issues with allocation concealment and dropout reporting.
  • Analyzed data on exacerbations, disease progression, and side effects.

Related Experiment Videos

Main Results:

  • Interferon treatment significantly reduced exacerbations (RR=0.80) and disease progression (RR=0.69) at two years.
  • Efficacy findings were sensitive to the handling of patient dropouts; significance was lost in a worst-case scenario analysis.
  • Quantitative analysis of MRI outcomes was not possible due to technological evolution and inconsistent data reporting.
  • Treatment-associated side effects were more frequent in interferon recipients; quality of life impact was not reported.

Conclusions:

  • Recombinant interferon demonstrated modest efficacy in reducing exacerbations and disease progression in RRMS over one to two years.
  • Methodological limitations, particularly concerning dropouts and inconsistent outcome reporting, hinder definitive conclusions.
  • Further research with longer follow-up and standardized outcome measures is needed to fully assess interferon's long-term impact on RRMS.